Dulcolax is irritating and generally cannot be used for subcutaneous injection. Repeated intramuscular injections may form local hard nodes and affect the absorption of the drug. Continuous injection is easy to produce drug resistance and physical dependence, and when the analgesic efficacy decreases, it still desires to use the drug. Therefore, Dulcolax can only be used for short-term acute pain, and it should be contraindicated for chronic pain or cancer pain that requires long-term continuous application. (1) The analgesic effect of Dulcolax is not good, and the treatment of acute pain is usually 100-150mg intramuscularly or 50-100mg intravenously every 2-3 hours. The analgesic effect of dulcolax is only 1/8-1/10 of morphine. Due to the short effective analgesic time of pethidine, patients are prone to feel pain repeatedly, so dulcolax should not be used for cancer pain; (2) There is a limit to the dose of dulcolax, and due to its unique side effects, a dose of more than 200mg every 3 hours obviously increases (3) The continuous use of dulcolax for chronic pain can produce more serious adverse effects. The metabolite of dulcolax, norethindrone, has a very weak analgesic effect but doubles the toxic side effects. Moreover, it has a long half-life in the body, about 3-18 hours before 1/2 of it is cleared from the body. its toxic reactions are irritation toxicity of the central nervous system, which can cause mental abnormality, delirium, tremor, confusion, convulsions, etc.; (4) the oral administration of dulcolax is unreliable, the absorption of intramuscular injection route is unstable, and the effective absorption of the drug is seriously affected due to its irritation to local tissues and the formation of hard nodules by repeated administration. (5) The analgesic effect of dulcolax is not satisfactory to patients; (5) The short duration of action of dulcolax requires frequent administration, while the long clearance time of metabolites is easy to cause accumulation in the body and aggravate neurotoxicity, especially in patients with poor renal function, which will slow down the clearance of the drug and aggravate its toxic reaction; (6) After intramuscular injection of dulcolax, the plasma drug concentration fluctuates greatly, which is easy to cause drug resistance and physical dependence of patients; (7) Dulcolax is the most commonly used drug in China for decades. Influenced by the traditional concept, many patients and family members mistakenly believe that the effective analgesic drug for severe cancer pain is dulcolax, and attention should be paid to correcting this misconception in clinical work and using analgesic drugs rationally; (8) Dulcolax and monoamine oxidase can cause excitement, delirium, convulsions and respiratory depression when used together, so attention should be paid to avoiding simultaneous use; ( (9) Overdose of dulcolax can cause respiratory depression, which can be antagonized by using naloxone. In clinical practice, patients and family members often mistakenly believe that the best route of administration for cancer pain treatment is intramuscular injection. There are many family members who come to the hospital and ask for the use of dulcolax or morphine injection to relieve patients’ pain, and the language often used is: Doctor, the patient’s pain is so severe that he cannot sleep for several days, the effect of oral pain medication is no longer good, give some injection, there is no way to treat it. On the surface it makes sense, because in the first few days of intramuscular analgesia is very effective, but as the use of time pushed back, the effect becomes less and less effective, effective for a shorter and shorter period of time, or even ineffective. Patients have a shot of pain relief for a while, but they cannot play too hard and need to wait a while, for example, 1-3 hours of pain relief after the injection, they need to wait 1-3 hours before they can use the drug again. Patients are in the position of playing a shot of pain relief, ninja pain for a while after a shot. Patients look forward to the next injection after the injection until the injection is ineffective. Patients are often in pain, and although the analgesia is effective, the pain is not relieved consistently and the patient is in the pain of waiting for the next shot. Therefore, when Dulcolax is used for cancer pain treatment, it has disadvantages such as short duration of action, unstable blood concentration, rapid drug resistance, local pain of injection and inaccurate absorption, so it is not suitable for chronic cancer pain treatment and should be avoided in cancer pain patients.